Thalidomide-related neuropathy

Johnson DC, Corthals SL, Walker BA et al (2011) Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 29 ... [Pg.322]

Lenalidomide is an immunomodulating agent related to thalidomide that was recently approved for the treatment of patients with multiple myeloma and myelodysplastic syndrome (MDS). Lenalidomide lacks the common side effects of thalidomide, such as constipation and peripheral neuropathy. Interim analyses of two phase III trials show that lenalidomide in combination with dexamethasone produces higher response rates than dexamethasone alone in relapsed and refractory myeloma. Adverse effects of lenalidomide include diarrhea, nausea, muscle cramps, hematologic side effects and deep vein thrombosis.42... [Pg.1423]

Adverse reactions include dose-related peripheral neuropathy (primarily sensory), nausea, vomiting, constipation, dry mouth, headache, and erythematous rashes. Dose-related central nervous system depression is relatively common. Thalidomide is contraindicated in pregnancy and in women of childbearing age. [Pg.2555]

Big Chemical Encyclopedia